New hope for kids with psoriasis: Real-World study shows cosentyx works

NCT ID NCT05388916

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 22 times

Summary

This study followed 42 children aged 6 to 17 with moderate to severe plaque psoriasis in China who were treated with Cosentyx (secukinumab) for up to 52 weeks. Researchers tracked side effects and how well the drug cleared skin symptoms. The goal was to see if Cosentyx is safe and effective in real-world pediatric care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Guangzhou, Guangdong, 510091, China
Novartis Investigative Site

Shijiazhuang, Hebei, 050000, China
Novartis Investigative Site

Zhengzhou, Henan, 450018, China
Novartis Investigative Site

Shenyang, Liaoning, 110004, China
Novartis Investigative Site

Xian, Shanxi, 710004, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310009, China
Novartis Investigative Site

Beijing, 100069, China

Conditions

Explore the condition pages connected to this study.

MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS